Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):
a. Avelumab + Axitinib
b. Axinitib
c. Cabozantinib
d. Everolimus
e. Lenvantinib + Everolimus
f. Nivolumab monotherapy
g. Nivolumab + Cabozantinib
h. Nivolumab + Ipilimumab
i. Pazopanib
j. Pembrolizumab monotherapy
k. Pembrolizumab + Lenvatinib
l. Pembrolizumab + Axitinib
m. Radiotherapy only
n. Sunitinib
o. Temsirolimus
p. Tivozanib
q. Other active systemic anti-cancer therapy
r. Palliative care only
Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib + Trametinib
d. Dacarbazine
e. Denosumab
f. Encorafenib + Binimetinib
g. Ipilimumab monotherapy
h. Ipilimumab + Nivolumab
i. Nivolumab monotherapy
j. Nivolumab + Relatlimab
k. Pembrolizumab
l. Trametinib
m. Vemurafenib
n. Vemurafenib + Cobimetinib
o. Other active systemic anti-cancer therapy
p. Palliative care only
Q3. Does you trust participate in any clinical trials for the treatment of melanoma? If so please provide the name of each trial and number of patients that are taking part?
